Novel antigenic targets of HPV therapeutic vaccines

Research output: Contribution to journal › Review › Research › peer-review

Standard

Novel antigenic targets of HPV therapeutic vaccines. / Boilesen, Ditte Rahbæk; Nielsen, Karen Nørgaard; Holst, Peter Johannes.

In: Vaccines, Vol. 9, No. 11, 1262, 2021.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Boilesen, DR, Nielsen, KN & Holst, PJ 2021, 'Novel antigenic targets of HPV therapeutic vaccines', Vaccines, vol. 9, no. 11, 1262. https://doi.org/10.3390/vaccines9111262

APA

Boilesen, D. R., Nielsen, K. N., & Holst, P. J. (2021). Novel antigenic targets of HPV therapeutic vaccines. Vaccines, 9(11), [1262]. https://doi.org/10.3390/vaccines9111262

Vancouver

Boilesen DR, Nielsen KN, Holst PJ. Novel antigenic targets of HPV therapeutic vaccines. Vaccines. 2021;9(11). 1262. https://doi.org/10.3390/vaccines9111262

Author

Boilesen, Ditte Rahbæk ; Nielsen, Karen Nørgaard ; Holst, Peter Johannes. / Novel antigenic targets of HPV therapeutic vaccines. In: Vaccines. 2021 ; Vol. 9, No. 11.

Bibtex

@article{9ad3cb99c59f4ec98913d689f066f962,

title = "Novel antigenic targets of HPV therapeutic vaccines",

abstract = "Human papillomavirus (HPV) infection is the cause of the majority of cervical cancers and head and neck cancers worldwide. Although prophylactic vaccines and cervical cancer screening programs have shown efficacy in preventing HPV-associated cervical cancer, cervical cancer is still a major cause of morbidity and mortality, especially in third world countries. Furthermore, head and neck cancer cases caused by HPV infection and associated mortality are increasing. The need for better therapy is clear, and therapeutic vaccination generating cytotoxic T cells against HPV proteins is a promising strategy. This review covers the current scene of HPV therapeutic vaccines in clinical development and discusses relevant considerations for the design of future HPV therapeutic vaccines and clinical trials, such as HPV protein expression patterns, immunogenicity, and exhaustion in relation to the different stages and types of HPV-associated lesions and cancers. Ultimately, while the majority of the HPV therapeutic vaccines currently in clinical testing target the two HPV oncoproteins E6 and E7, we suggest that there is a need to include more HPV antigens in future HPV therapeutic vaccines to increase efficacy and find that especially E1 and E2 could be promising novel targets.",

keywords = "Human papillomavirus, Therapeutic vaccines",

author = "Boilesen, {Ditte Rahb{\ae}k} and Nielsen, {Karen N{\o}rgaard} and Holst, {Peter Johannes}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

doi = "10.3390/vaccines9111262",

language = "English",

volume = "9",

journal = "Vaccines",

issn = "2076-393X",

publisher = "MDPI AG",

number = "11",

}

RIS

TY - JOUR

T1 - Novel antigenic targets of HPV therapeutic vaccines

AU - Boilesen, Ditte Rahbæk

AU - Nielsen, Karen Nørgaard

AU - Holst, Peter Johannes

PY - 2021

Y1 - 2021

N2 - Human papillomavirus (HPV) infection is the cause of the majority of cervical cancers and head and neck cancers worldwide. Although prophylactic vaccines and cervical cancer screening programs have shown efficacy in preventing HPV-associated cervical cancer, cervical cancer is still a major cause of morbidity and mortality, especially in third world countries. Furthermore, head and neck cancer cases caused by HPV infection and associated mortality are increasing. The need for better therapy is clear, and therapeutic vaccination generating cytotoxic T cells against HPV proteins is a promising strategy. This review covers the current scene of HPV therapeutic vaccines in clinical development and discusses relevant considerations for the design of future HPV therapeutic vaccines and clinical trials, such as HPV protein expression patterns, immunogenicity, and exhaustion in relation to the different stages and types of HPV-associated lesions and cancers. Ultimately, while the majority of the HPV therapeutic vaccines currently in clinical testing target the two HPV oncoproteins E6 and E7, we suggest that there is a need to include more HPV antigens in future HPV therapeutic vaccines to increase efficacy and find that especially E1 and E2 could be promising novel targets.

AB - Human papillomavirus (HPV) infection is the cause of the majority of cervical cancers and head and neck cancers worldwide. Although prophylactic vaccines and cervical cancer screening programs have shown efficacy in preventing HPV-associated cervical cancer, cervical cancer is still a major cause of morbidity and mortality, especially in third world countries. Furthermore, head and neck cancer cases caused by HPV infection and associated mortality are increasing. The need for better therapy is clear, and therapeutic vaccination generating cytotoxic T cells against HPV proteins is a promising strategy. This review covers the current scene of HPV therapeutic vaccines in clinical development and discusses relevant considerations for the design of future HPV therapeutic vaccines and clinical trials, such as HPV protein expression patterns, immunogenicity, and exhaustion in relation to the different stages and types of HPV-associated lesions and cancers. Ultimately, while the majority of the HPV therapeutic vaccines currently in clinical testing target the two HPV oncoproteins E6 and E7, we suggest that there is a need to include more HPV antigens in future HPV therapeutic vaccines to increase efficacy and find that especially E1 and E2 could be promising novel targets.

KW - Human papillomavirus

KW - Therapeutic vaccines

U2 - 10.3390/vaccines9111262

DO - 10.3390/vaccines9111262

M3 - Review

C2 - 34835193

AN - SCOPUS:85118742340

VL - 9

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 11

M1 - 1262

ER -

ID: 285311418

Department of Biomedical Sciences